Tag Archives: pulmonary diseases

March, 2017

December, 2016

October, 2016

  • 5 October

    AstraZeneca Licenses Pulmonary Drug to Insmed in $150 Million+ Deal

    BRIDGEWATER, N.J., Oct. 05, 2016 (GLOBE NEWSWIRE) — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known …

August, 2016

  • 17 August

    Vertex to Stop of Experimental Cystic Fibrosis Phase 3 Combo Trial

    BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility …

June, 2015

May, 2015

March, 2015

  • 17 March

    Respiratory Biotech Pulmatrix to Merge with Ruthigen

    Respiratory biotech Pulmatrix announced an agreement to merge with publicly traded, biopharmaceutical company Ruthigen. The companies have entered into a definitive merger agreement, under which Pulmatrix will become a wholly-owned subsidiary of Ruthigen – which would take the Pulmatrix name and continue Pulmatrix’s work of advancing a new generation of …